OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.75
+0.19%0
Insider buys (3m)
1
Insider sells (3m)
-$144.7K
Net value (3m)
+4.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | O'Byrne Jason · officer: CHIEF FINANCIAL OFFICER | A-Award | 650,000 | $11 |
| Jul 27, 2026 | Harmon Cyrus · director | Sale | 12,500 | $12 |
| Jun 23, 2026 | RAPPAPORT ANDREW · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | Graham G. Walmsley · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | Horning Sandra · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | Raman Prakash · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | BVF PARTNERS L P/IL · director, other: See Explanation of Responses | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | Harmon Cyrus · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | BUTITTA CYNTHIA M · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | Garland J. Scott · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | Hrustanovic Gorjan · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | CLARK IAN T · director | A-Award | 29,500 | $9.51 |
| Jun 23, 2026 | Larson Yi · director | A-Award | 29,500 | $9.51 |
| Apr 29, 2026 | Raman Prakash · director | A-Award | 24,150 | $15 |
| Apr 29, 2026 | Raman Prakash · director | A-Award | 2,911 | $15 |
| Mar 5, 2026 | Mitchell Shawnte · officer: CHIEF LEGAL OFFICER | Sale | 24,767 | $24 |
| Mar 5, 2026 | Mitchell Shawnte · officer: CHIEF LEGAL OFFICER | M-Exempt | 25,000 | $4.37 |
| Mar 5, 2026 | Mitchell Shawnte · officer: CHIEF LEGAL OFFICER | M-Exempt | 15,000 | $4.37 |
| Mar 5, 2026 | Mitchell Shawnte · officer: CHIEF LEGAL OFFICER | Sale | 233 | $25 |
| Mar 5, 2026 | Mitchell Shawnte · officer: CHIEF LEGAL OFFICER | Sale | 15,000 | $23 |
| Feb 17, 2026 | Austin Sasha Lu · officer: VP of Finance and Controller | A-Award | 29,250 | $26 |
| Feb 17, 2026 | Austin Sasha Lu · officer: VP of Finance and Controller | A-Award | 11,700 | $0.00 |
| Feb 4, 2026 | Zojwalla Naseem · officer: CHIEF MEDICAL OFFICER | A-Award | 250,000 | $26 |
| Feb 4, 2026 | Bohen Sean · director, officer: PRESIDENT AND CEO | A-Award | 275,000 | $26 |
| Feb 4, 2026 | Bohen Sean · director, officer: PRESIDENT AND CEO | A-Award | 850,000 | $26 |
| Feb 4, 2026 | Mitchell Shawnte · officer: CHIEF LEGAL OFFICER | A-Award | 56,250 | $26 |
| Feb 4, 2026 | Mitchell Shawnte · officer: CHIEF LEGAL OFFICER | A-Award | 220,000 | $26 |
| Feb 4, 2026 | Myles David C. · officer: CH. DISCOV. & NON-CLIN DEV OFF | A-Award | 106,250 | $26 |
| Feb 4, 2026 | Myles David C. · officer: CH. DISCOV. & NON-CLIN DEV OFF | A-Award | 250,000 | $26 |
| Feb 4, 2026 | Zojwalla Naseem · officer: CHIEF MEDICAL OFFICER | A-Award | 106,250 | $26 |
Institutional positioning
13F filings over the trailing two quarters
New 75Increased 149Reduced 117Sold out 39
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 12,143,062 | Aug 13, 2026 |
| FMR LLC | Increased | 10,386,845 | May 15, 2026 |
| Paradigm Biocapital Advisors LP | Increased | 8,670,576 | Aug 14, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 8,020,576 | May 15, 2026 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Reduced | 7,473,238 | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 7,108,488 | May 18, 2026 |
| Jupiter Topco LLC | New Position | 7,094,413 | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | Reduced | 7,085,249 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 6,714,691 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 5,652,135 | May 13, 2026 |
| BVF INC/IL | Unchanged | 5,295,893 | Aug 14, 2026 |
| BVF INC/IL | Unchanged | 5,295,893 | May 15, 2026 |
| Siren, L.L.C. | Increased | 4,856,949 | Aug 13, 2026 |
| SIREN, L.L.C. | Increased | 4,756,949 | May 14, 2026 |
| CORMORANT ASSET MANAGEMENT, LP | Increased | 4,400,000 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 2, 2026